» Articles » PMID: 17991878

Adiponectin Inhibits the Production of CXC Receptor 3 Chemokine Ligands in Macrophages and Reduces T-lymphocyte Recruitment in Atherogenesis

Overview
Journal Circ Res
Date 2007 Nov 10
PMID 17991878
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Obese individuals often have low plasma adiponectin and concomitant chronic inflammation with a predisposition to metabolic and cardiovascular diseases. The present study reports a novel antiinflammatory action of adiponectin in human monocyte-derived macrophages (MPhi) suppressing T-lymphocyte accumulation in atherogenesis. RNA profiling of lipopolysaccharide-stimulated human MPhi identified CXC chemokine ligands (CXCLs), such as IP-10 (interferon [IFN]-inducible protein 10) (CXCL10), I-TAC (IFN-inducible T-cell alpha chemoattractant) (CXCL11), and Mig (monokine induced by IFN-gamma) (CXCL9), T-lymphocyte chemoattractants associated with atherogenesis, among the top 14 transcripts suppressed by adiponectin. Real-time quantitative RT-PCR and ELISA verified that adiponectin inhibited expression of these chemokines at both the mRNA and protein levels in a concentration-dependent manner. Adiponectin reduced the release by lipopolysaccharide-stimulated MPhi of chemoattractant activity for CXC chemokine receptor 3-transfected (receptor for IP-10, Mig, and I-TAC) lymphocytes. Adiponectin decreased lipopolysaccharide-inducible IP-10 promoter activity in promoter-transfected THP-1 MPhi but did not change IP-10 mRNA stability. In lipopolysaccharide-stimulated MPhi, reduction of IFN-beta by adiponectin preceded inhibition of IP-10 mRNA expression. Immunoblot and chromatin immunoprecipitation analyses demonstrated that adiponectin attenuated activation of the transcription factor IFN regulatory factor 3, involved in the MyD88-independent pathway of Toll-like receptor 4 signaling, and subsequent IFN regulatory factor 3 binding to IFN-beta promoter. In vivo studies further demonstrated that apolipoprotein E/adiponectin double-deficient (apoE-/-APN-/-) mice had increased plasma IP-10 levels, accelerated T-lymphocyte accumulation in atheromata, and augmented atherogenesis compared with apoE single-deficient (apoE-/-APN+/+) mice. This study establishes that low levels of adiponectin associated with obesity, the metabolic syndrome, and diabetes favor T-lymphocyte recruitment and contribute to adaptive immune response during atherogenesis.

Citing Articles

Transcription and post-translational mechanisms: dual regulation of adiponectin-mediated Occludin expression in diabetes.

Duan Y, Liu D, Yu H, Zhang S, Xia Y, Du Z Cell Biosci. 2024; 14(1):126.

PMID: 39354565 PMC: 11443667. DOI: 10.1186/s13578-024-01306-5.


Therapeutic potential of adiponectin in prediabetes: strategies, challenges, and future directions.

Abdalla M Ther Adv Endocrinol Metab. 2024; 15:20420188231222371.

PMID: 38250316 PMC: 10798122. DOI: 10.1177/20420188231222371.


G. Forst Intake Reduces the Cardiovascular Disease Plasmatic Markers Associated with a High-Fat Diet in a Mice Model.

Olivares-Caro L, Nova-Baza D, Radojkovic C, Bustamante L, Duran D, Mennickent D Antioxidants (Basel). 2023; 12(2).

PMID: 36829862 PMC: 9952125. DOI: 10.3390/antiox12020304.


Crosstalk Between Adipose Tissue and the Heart: An Update.

Li C, Sun X, Zhao S, Scherer P J Transl Int Med. 2023; 10(3):219-226.

PMID: 36776231 PMC: 9901553. DOI: 10.2478/jtim-2022-0039.


Adipose Tissue Paracrine-, Autocrine-, and Matrix-Dependent Signaling during the Development and Progression of Obesity.

Johnston E, Abbott R Cells. 2023; 12(3).

PMID: 36766750 PMC: 9913478. DOI: 10.3390/cells12030407.